Sunday, March 23, 2025

HomeHealth NewsTreating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism

Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanism

- Advertisement -

The proposed model for FGF21-activated PPP6C in treating liver Fibrosis and metabolic dysfunction-associated steatohepatitis. Credit: Prof. Li Yu’s group

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have shown promise in clinical trials, their underlying…

Click here to view the original article.

- Advertisment -

Recently Viewed